Related Experiment Videos
Plasmatic endothelin-1 levels in hyperthyroid patients before and after antithyroid therapy
R Cesareo1, A Tarabuso, M Di Benedetto
1Division of Internal Medicine, Ciriè Hospital, Via Battitore-10073 Ciriè, TO.
Minerva Endocrinologica
|January 10, 2001
Summary
Hyperthyroidism elevates Endothelin-1 (ET-1) levels, a vasoconstrictor peptide. Antithyroid therapy normalizes these levels, suggesting ET-1 may serve as a thyroid function index.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
Background:
- Endothelin-1 (ET-1) is a potent vasoconstrictor peptide implicated in vascular diseases.
- Elevated ET-1 plasma levels are observed in hyperthyroidism and other endocrine disorders.
Purpose of the Study:
- To investigate the impact of antithyroid therapy on ET-1 plasma levels in hyperthyroid patients.
- To explore the relationship between ET-1 levels and thyroid metabolic activity.
Main Methods:
- Measured ET-1 plasma levels in 14 hyperthyroid patients before and at 2 and 6 months after methimazole treatment.
- Compared ET-1 levels to those of control subjects.
Main Results:
- Hyperthyroid patients exhibited significantly higher ET-1 levels than controls (18.85 ± 5.7 vs 10.9 ± 2.1 pg/ml).
- Antithyroid therapy normalized ET-1 levels, resulting in no significant difference compared to controls.
- ET-1 plasma levels strongly correlated with thyroid metabolic activity.
Conclusions:
- Increased ET-1 levels in hyperthyroidism may reflect vascular damage induced by high thyroid hormone levels.
- ET-1 plasma levels could potentially serve as a functional index for hyperthyroid diseases in the future.